id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-289890-sf2uxubd	Rushworth, S. A.	Performance and health economic evaluation of the Mount Sinai COVID-19 serological assay identifies modification of thresholding as necessary to maximise specificity of the assay	2020-06-12		.txt	text/plain	3954	195	52	We evaluated the FDA approved SARS-CoV-2 immunoassay (developed at Mount Sinai, by Krammer and colleagues) for the identification of COVID-19 seroconversion and potential cross-reactivity of the assay in a United Kingdom (UK) National Health Service (NHS) hospital setting. In summary, we report that the Mount Sinai IgG ELISA assay is highly sensitive test for SARS-Cov-2 infection, however modification of thresholding was required to minimise false positive results. Figure 2A shows that 42/47 samples from this group were established as negative for SARS-CoV-2 IgG antibody in the first RBD screening test step, and 5/47 required confirmatory assessment with the second dilution assay. On testing of the control group, 70/72 patient samples were identified as being negative for SARS-CoV-2 IgG antibody following the RBD step of the assay using the 5 SD threshold. To conclude, here we report that the Mount Sinai IgG ELISA assay is highly sensitive and apparent cost-effective test for SARS-Cov-2 infection in a UK NHS acute hospital laboratory setting.	./cache/cord-289890-sf2uxubd.txt	./txt/cord-289890-sf2uxubd.txt